Assembly Biosciences (NASDAQ:ASMB) was downgraded by stock analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a report issued on Wednesday.

ASMB has been the subject of a number of other reports. Chardan Capital restated a “buy” rating on shares of Assembly Biosciences in a report on Sunday, September 17th. Zacks Investment Research upgraded shares of Assembly Biosciences from a “hold” rating to a “buy” rating and set a $37.00 price objective for the company in a report on Wednesday, November 15th. Finally, Jefferies Group began coverage on shares of Assembly Biosciences in a report on Wednesday, November 8th. They issued a “buy” rating and a $50.00 price objective for the company. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $40.67.

Shares of Assembly Biosciences (NASDAQ:ASMB) traded up $1.39 on Wednesday, hitting $44.28. Assembly Biosciences has a 52 week low of $11.07 and a 52 week high of $52.37.

In related news, Director William R. Ringo sold 1,000 shares of Assembly Biosciences stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $29.55, for a total value of $29,550.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Over the last 90 days, insiders sold 3,000 shares of company stock valued at $112,620. Company insiders own 19.60% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of ASMB. State Street Corp purchased a new position in shares of Assembly Biosciences in the second quarter worth $4,234,000. JPMorgan Chase & Co. purchased a new position in shares of Assembly Biosciences in the second quarter worth $3,426,000. Valeo Financial Advisors LLC purchased a new position in shares of Assembly Biosciences in the third quarter worth $4,963,000. Northern Trust Corp increased its stake in shares of Assembly Biosciences by 221.2% in the second quarter. Northern Trust Corp now owns 195,321 shares of the biopharmaceutical company’s stock worth $4,033,000 after buying an additional 134,513 shares during the period. Finally, AXA purchased a new position in shares of Assembly Biosciences in the second quarter worth $2,477,000. 62.09% of the stock is currently owned by institutional investors.

WARNING: This story was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/12/10/assembly-biosciences-asmb-downgraded-by-bidaskclub.html.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.

Receive News & Ratings for Assembly Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.